<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718144</url>
  </required_header>
  <id_info>
    <org_study_id>PR3106</org_study_id>
    <nct_id>NCT02718144</nct_id>
  </id_info>
  <brief_title>Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer</brief_title>
  <official_title>A Phase I/II Clinical Trial Assessing Safety and Efficacy of Estetrol (E4) in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pantarhei Oncology B.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pantarhei Oncology B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3
      cohort design to determine the recommended dose of estetrol for the treatment of patients
      with advanced breast cancer. After completing phase I part of the study (i.e. 4 weeks of
      treatment), patients will receive further treatment for 8 weeks at their individual phase I
      dose level (phase IIa part of the study).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with a dose limiting toxicity (DLT)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire on estrogen deficiency symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of Life will be assessed by means of a questionnaire on estrogen deficiency symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: estetrol trough levels</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumour response according to RECIST 1.1</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with Adverse Events (AEs)</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>estetrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 + 3 design with inter-patient dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estetrol</intervention_name>
    <description>Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.</description>
    <arm_group_label>estetrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with ER-positive and HER2-negative locally advanced and/or
             metastatic breast cancer, who progressed on standard therapies or for whom standard
             therapies are intolerant;

          -  Patients should have experienced a natural or surgical menopause at least 5 years ago;

          -  Failure of anti-estrogen treatment with tamoxifen and aromatase inhibitor(s) due to
             the development of resistance or unacceptable side effects with this treatment;

          -  No undiagnosed vaginal bleeding;

          -  No treatment with fulvestrant within 6 months of start of treatment;

          -  Life expectancy at least 6 months;

          -  Tumour assessment (CT scan) within 28 days before the start of the E4 treatment;

          -  Body mass index (BMI) between (≥) 18 and (≤) 35 kg/m2;

          -  Able to swallow an oral medication;

          -  Acceptable values of hematological parameters, liver and kidney function and calcium
             levels;

          -  Reasonable physical and mental health as judged by the investigator and determined by
             physical examination, clinical laboratory assessments and vital signs;

          -  Willing to give informed consent in writing.

        Exclusion Criteria:

          -  Uncontrolled nausea, vomiting, or diarrhea;

          -  History of venous or arterial thromboembolic disease or a known defect in the blood
             coagulation system;

          -  Uncontrolled hypertension, i.e. systolic blood pressure 160 mmHg and/or diastolic
             blood pressure 100 mmHg in the last 6 months with or without medication;

          -  Diabetes mellitus with poor glycaemic control in the last 6 months (HbA1c above 7.5%);

          -  Any other serious disease including systemic lupus erythematosus and untreated
             cholelithiasis;

          -  Smoking &gt;10 cigarettes/day;

          -  Use of any other cancer therapy including radiotherapy (except for palliative
             reasons), endocrine therapy, immunotherapy, chemotherapy, or use of other
             investigational agents at the start of treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carole Verhoeven, PhD</last_name>
    <phone>+31 30 6985020</phone>
    <email>cv@pantarheibio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Katholisches Klinikum Koblenz Montabaur</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Dunnebacke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Dr Honig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Dr Schmidt</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Singer CF, Bennink HJ, Natter C, Steurer S, Rudas M, Moinfar F, Appels N, Visser M, Kubista E. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014 Nov;35(11):2447-51. doi: 10.1093/carcin/bgu144. Epub 2014 Jul 5.</citation>
    <PMID>24997853</PMID>
  </results_reference>
  <results_reference>
    <citation>Visser M, Kloosterboer HJ, Bennink HJ. Estetrol prevents and suppresses mammary tumors induced by DMBA in a rat model. Horm Mol Biol Clin Investig. 2012 Apr 1;9(1):95-103. doi: 10.1515/hmbci-2012-0015.</citation>
    <PMID>25961355</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dose-escalation</keyword>
  <keyword>safety</keyword>
  <keyword>dose-limiting toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

